Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
Marion de Jong(Shell (Netherlands)), Eric P. Krenning(Cyclotron (Netherlands)), C Smith(UCLouvain), Larry K. Kvols(Moffitt Cancer Center), François Jamar(Cliniques Universitaires Saint-Luc), Willem H. Bakker(Erasmus MC), Wout A. P. Breeman(Uppsala University Hospital), Dik J. Kwekkeboom(Erasmus MC), Stanislas Pauwels, Roelf Valkema(Active Medicine (United Kingdom))
Cited by 347
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814